DZ2676A1 - Solution aqueuse et composition pharmaceutique buvable à base de chloridrate de 1-Ä2-(2-naphtyl)ethyl)Ü-4-(3-triphluoromethylphenyl)-1,2,3,6-tetrahydropyridine et complexe dudit chlorhydrate avec la beta-cyclodextrine. - Google Patents

Solution aqueuse et composition pharmaceutique buvable à base de chloridrate de 1-Ä2-(2-naphtyl)ethyl)Ü-4-(3-triphluoromethylphenyl)-1,2,3,6-tetrahydropyridine et complexe dudit chlorhydrate avec la beta-cyclodextrine.

Info

Publication number
DZ2676A1
DZ2676A1 DZ980286A DZ980286A DZ2676A1 DZ 2676 A1 DZ2676 A1 DZ 2676A1 DZ 980286 A DZ980286 A DZ 980286A DZ 980286 A DZ980286 A DZ 980286A DZ 2676 A1 DZ2676 A1 DZ 2676A1
Authority
DZ
Algeria
Prior art keywords
triphluoromethylphenyl
chloridrate
tetrahydropyridine
cyclodextrin
naphthyl
Prior art date
Application number
DZ980286A
Other languages
English (en)
French (fr)
Inventor
Claude Aleman
Philippe Bastard
Marielle Bonnel
Thierry Breul
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Application granted granted Critical
Publication of DZ2676A1 publication Critical patent/DZ2676A1/xx

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Physical Or Chemical Processes And Apparatus (AREA)
DZ980286A 1997-12-24 1998-12-15 Solution aqueuse et composition pharmaceutique buvable à base de chloridrate de 1-Ä2-(2-naphtyl)ethyl)Ü-4-(3-triphluoromethylphenyl)-1,2,3,6-tetrahydropyridine et complexe dudit chlorhydrate avec la beta-cyclodextrine. DZ2676A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9716529A FR2772614B1 (fr) 1997-12-24 1997-12-24 Solution aqueuse a base de chlorhydrate de 1- [ 2-(2-naphtyl)ethyl]-4- (3-trifluoromethylphenyl) -1,2,3,6-tetrahydropyridine et composition pharmaceutique buvable en contenant

Publications (1)

Publication Number Publication Date
DZ2676A1 true DZ2676A1 (fr) 2004-09-19

Family

ID=9515152

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980286A DZ2676A1 (fr) 1997-12-24 1998-12-15 Solution aqueuse et composition pharmaceutique buvable à base de chloridrate de 1-Ä2-(2-naphtyl)ethyl)Ü-4-(3-triphluoromethylphenyl)-1,2,3,6-tetrahydropyridine et complexe dudit chlorhydrate avec la beta-cyclodextrine.

Country Status (25)

Country Link
US (1) US6191137B1 (de)
EP (1) EP1041984B1 (de)
JP (1) JP2002510599A (de)
AR (1) AR017722A1 (de)
AT (1) ATE252384T1 (de)
AU (1) AU1880599A (de)
BR (1) BR9814414A (de)
CA (1) CA2315696C (de)
CO (1) CO4970813A1 (de)
DE (1) DE69819203T2 (de)
DK (1) DK1041984T3 (de)
DZ (1) DZ2676A1 (de)
ES (1) ES2209238T3 (de)
FR (1) FR2772614B1 (de)
GT (1) GT199800204A (de)
HU (1) HUP0101012A3 (de)
MY (1) MY117156A (de)
NO (1) NO20003284L (de)
PT (1) PT1041984E (de)
SA (2) SA99191002B1 (de)
SI (1) SI1041984T1 (de)
TW (1) TW536409B (de)
UY (1) UY25320A1 (de)
WO (1) WO1999033466A1 (de)
ZA (1) ZA9811824B (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087870A2 (en) * 2003-03-25 2004-10-14 The Johns Hopkins University Neuronal cell lineages and methods of production thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2702656B1 (fr) * 1993-03-18 1995-06-16 Sanofi Elf Utilisation de derives de la tetrahydropyridine pour la preparation de medicaments cardioprotecteurs.

Also Published As

Publication number Publication date
US6191137B1 (en) 2001-02-20
HUP0101012A3 (en) 2002-12-28
ATE252384T1 (de) 2003-11-15
EP1041984A1 (de) 2000-10-11
CO4970813A1 (es) 2000-11-07
SA99191003B1 (ar) 2006-10-02
DE69819203T2 (de) 2004-07-15
CA2315696C (en) 2008-01-29
DK1041984T3 (da) 2004-02-16
FR2772614B1 (fr) 2000-03-10
HUP0101012A2 (hu) 2001-08-28
NO20003284D0 (no) 2000-06-22
AU1880599A (en) 1999-07-19
ZA9811824B (en) 1999-06-29
AR017722A1 (es) 2001-09-12
JP2002510599A (ja) 2002-04-09
DE69819203D1 (de) 2003-11-27
ES2209238T3 (es) 2004-06-16
EP1041984B1 (de) 2003-10-22
SI1041984T1 (en) 2004-04-30
BR9814414A (pt) 2000-10-10
PT1041984E (pt) 2004-02-27
NO20003284L (no) 2000-08-24
WO1999033466A1 (fr) 1999-07-08
FR2772614A1 (fr) 1999-06-25
SA99191002B1 (ar) 2006-03-07
TW536409B (en) 2003-06-11
UY25320A1 (es) 2000-10-31
GT199800204A (es) 2000-06-14
CA2315696A1 (en) 1999-07-08
MY117156A (en) 2004-05-31

Similar Documents

Publication Publication Date Title
DE69822209D1 (de) ESTRON-SULFatase HEMMENDE ESTRON-SULFAMATVERBINDUNGEN, PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND VERWENDUNGEN DAVON
GEP20032995B (en) 1-Amino-Alkylcyclohexane NMDA Receptor Antagonists
BR9804500B1 (pt) derivado de amida, referida composição farmacêutica e agente terapêutico.
BR9813284B1 (pt) aminoácidos cìclicos e derivados dos mesmos úteis como agentes farmacêuticos e composição farmacêutica.
ATE284223T1 (de) Zusammensetzung enthaltend ein tramadol und ein antikonvulsives arzneimittel
FR2784678B1 (fr) Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
FR2783246B1 (fr) Derives d'azetidine, leur preparation et les medicaments les contenant
EE200100495A (et) Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim
DE69812433D1 (de) Anti-estrogene steroide, pharmazeutische zusammensetzungen und verwendungen davon
HUP0401567A3 (en) Novel 4,5-dyhydro-1h-pyrazole derivatives having cb1-antagonistic activity, their use and pharmaceutical compositions containing them
DE69836424D1 (de) Laktose-freie, nicht-hygroskopische und wasserfreie pharmazeutische zusammensetzungen von descarboethoxyloratadin
DK199900176U3 (da) Paroxetinsalte, farmaceutisk præparat indeholdende disse og anvendelser deraf
FR2764889B1 (fr) Nouveaux derives du 2-(iminomethyl)amino-phenyle, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
NO20040702L (no) Kombinerte preparater som inneholder 1,4-benzotiepin-1,1-dioksidderivater og andre aktive substanser og anvendelsen derav
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
DE60117527D1 (de) Pigmentzubereitungen und damit hergestellte wässrige effektbasislacke
EE04493B1 (et) Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks
HUP0000960A3 (en) Spray-dried paroxetine hydrochloride, process for it's preparation,use of the compound and pharmaceutical compositions containing the same
DE69519368D1 (de) Neue antiandrogenen mitteln pharmazeutische präparate und verwendungen davon
NO20000519L (no) 2-acylaminopropanaminer som takykininreseptorantagonister
DE60115997D1 (de) 1,1- and 1,2-Disubstituierte Cyclopropane, Verfahren zu deren Herstellung und deren pharmazeutischen Zusammensetzungen
DZ2676A1 (fr) Solution aqueuse et composition pharmaceutique buvable à base de chloridrate de 1-Ä2-(2-naphtyl)ethyl)Ü-4-(3-triphluoromethylphenyl)-1,2,3,6-tetrahydropyridine et complexe dudit chlorhydrate avec la beta-cyclodextrine.
EE04347B1 (et) 8-asabitsüklo[3.2.1]oktaan-3-metaanamiini derivaadid, neid sisaldav ravim ja farmatseutiline kompositsioon
DZ3055A1 (fr) Polymorphes d'un chlorhydrate d'azo-bicyclo-2,2,2-oct-3-ylamine cristallins et compositions pharmaceutiques les contenant.
KR970061248A (ko) 알츠하이머병 치료용 1, 1, 2-트리페닐부트-1-엔 유도체